Linked Life Data

3556412

Source:http://linkedlifedata.com/resource/pubmed/id/3556412

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1987-5-1
pubmed:abstractText
The authors administered to six transsexual women at three-month intervals androgenic depot preparations: testosterone undecanoate (Andriol-Organon) by the oral route and testosterone isobutyrate (Agovirin depot-Spofa) in injections. The achieved changes were evaluated by clinical and laboratory examinations, i.e. somatic changes as well as changes of hormonal indicators in plasma, urine and saliva, changes in the TeBG binding capacity, the effect of the administered hormones on liver functions, glucose metabolism and secretory insulin response. The high plasma androgen level did not vary substantially. After Andriol administration, a significant decrease of plasma TeBG was achieved, and an increase of the free testosterone fraction in saliva which was retained three months after discontinuation of the treatment. Both preparations caused the required virilization, whereby the action of Agovirin depot-Spofa in the selected dose was, as regards the speed of onset and intensity of the androgenization symptoms, more effective. The gonadotropin levels were not changed significantly during short-term administration. No interference with liver functions and glucose metabolism was observed. The patients tolerated both preparations well.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0232-7384
pubmed:author
pubmed:issnType
Print
pubmed:volume
88
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
219-23
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1986
pubmed:articleTitle
Androgen administration to transsexual women. II. Hormonal changes.
pubmed:publicationType
Journal Article